Beaver Run Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)

Scientific Organizers: Christian Klein, Mark S. Cragg and Germaine Fuh


April 7—11, 2019

Beaver Run Resort, Breckenridge, Colorado, USA


Sponsored by AbbVie Inc., Bioverativ Therapeutics, ImmunoGen, Inc., Incyte Corporation, Merck & Co., Inc., MorphoSys AG, Roche and Valerion Therapeutics


Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.
BEWARE of booking lodging through companies unaffiliated with Keystone Symposia. Click here for more details.

Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.

DEADLINES:
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: Dec 11, 2018 [details]
Discounted Abstract Deadline: Dec 11, 2018 [details]
Abstract Deadline: Jan 9, 2019 [details]
Discounted Registration Deadline: Feb 6, 2019 [details]


If you have missed a deadline due to the US government shutdown, please contact our office.

Click here to view Cancellation Policy

Register Yourself Deadlines and Fees

Rates and Deadlines listed below are for the 2019-D2 "Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies" conference only.

*All deadlines end at 11:59 PM US Mountain Standard Time

Deadline Date Cost
Discounted Abstract Deadline
More details
Before and On December 11, 2018 100.00 USD*
- 50.00 USD discount
Abstract Deadline
More details
After December 11, 2018 until February 24, 2019 100.00 USD*
* 50.00 USD of Abstract fee deducted from your registration fee when you register for this meeting
Scholarship
More details
December 11, 2018 n/a
Discounted NON-STUDENT Registration
More details
Before and On February 6, 2019 845.00 USD
(includes 200.00 discount)
Regular NON-STUDENT Registration
More details
After February 6, 2019 1045.00 USD
Discounted STUDENT Registration
More details
Before and On February 6, 2019 620.00 USD
(includes 200.00 discount)
Regular STUDENT Registration
More details
After February 6, 2019 820.00 USD

* Changes in payment type that result in a refund are subject to a processing fee.
* Currency exchange gains/losses are the responsibility of the registrant and the Keystone Symposia will accept no liability for money loss through bank charges, transfers or currency fluctuations.




Discounted Abstract Deadline: December 11, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time

Abstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register

Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract early allows us to:
  • submit your abstract to organizers to be considered for a short talk
  • accept your abstract online
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
(The Abstract Deadline: is January 9, 2019)

Global Health Travel Award Deadline:

*All deadlines end at 11:59 PM US Mountain Standard Time


Global Health Travel Award Details: You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline and complete the other required steps (verify your contact information and submit a recommendation letter) to be considered for a travel award.


Click here to learn more about Global Health Travel Awards.

Scholarship Deadline: December 11, 2018

*All deadlines end at 11:59 PM US Mountain Standard Time


Scholarship Details: You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.

Click here to learn more about Scholarships.

Abstract Deadline: January 9, 2019

*All deadlines end at 11:59 PM US Mountain Standard Time


Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register

Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.

Submitting your abstract by the Abstract Deadline allows us to:

  • submit your abstract to organizers to be considered for a short talk
  • include your abstract on our website and in our secure mobile app
  • reserve your space at the meeting for a poster presentation.**
**Submitting an abstract does not constitute or guarantee registration.
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.

(Discounted Abstract Deadline: is December 11, 2018)

Discounted Registration Deadline: February 6, 2019

*All deadlines end at 11:59 PM US Mountain Standard Time


Registration Fee: 845.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

After the Discounted Registration Deadline:


Registration Fee: 1045.00 USD*
Student Registration Fee: 820.00 USD* (must complete student verification form)

*Includes 50.00 USD of your abstract submission fee

Registration spaces are limited and may fill prior to discounted registration deadline.

Please be advised that some meeting participants have received calls and emails from a number of different housing services, including "Exhibitors Housing Services," “Expo Housing Services,” "Global Housing," etc. THESE COMPANIES ARE NOT AFFILIATED WITH KEYSTONE SYMPOSIA and are not authorized by Keystone Symposia to contact you. These companies may tell you that the meeting is filling, without any actual knowledge to that effect, and pressure you into giving them your credit card number to make a lodging reservation with them.

We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.

SUNDAY, APRIL 7

16:00—20:00
Arrival and Registration

Colorado Ballroom Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Colorado Ballroom Foyer

MONDAY, APRIL 8

07:00—08:00
Breakfast

Summit Gallery
08:00—09:30
Welcome and Keynote Session
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
* Christian Klein, Roche, Switzerland

George D. Yancopoulos, Regeneron Pharmaceuticals, Inc., USA
Target Identification and Developing Antibodies for Clinical Application

Jennifer R. Cochran, Stanford University, USA
Emerging Strategies for Developing Next-Generation Protein Therapeutics

Coffee Break

09:50—11:45
Mechanisms of Action for Depleting Antibodies
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
* Janine Schuurman, Genmab B.V., Netherlands

Mark S. Cragg, University of Southampton, UK
Targeting B Cells with Antibodies: From Oncology to Autoimmunity

Falk Nimmerjahn, Universitätsklinikum Erlangen, Germany
The Where, When, and How: Organ Specific Pathways of Cytotoxic IgG Activity

Annalee W. Nguyen, University of Texas at Austin, USA
Short Talk: Antibodies Engineered for Enhanced Binding and Effector Activity in the Low pH of the Tumor Microenvironment

Polina Weitzenfeld, Rockefeller University, USA
Short Talk: Antibody Targeting of Carbohydrate-Associated Tumor Antigens Reveals Novel Effector Cell Pathways for Tumor Clearance

Michael Schmidt, Compass Therapeutics, USA
Short Talk: Novel Class of NK Engagers Targeting NKp30 Selected from Unbiased Screen of Common Light Chain-Based Bispecific Antibodies

11:45—17:00
On Own for Lunch

11:45—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
14:30—16:30
Workshop 1: Engineering (Bispecific) Antibodies

Colorado Ballroom
* Christian Klein, Roche, Switzerland

Starlynn Clarke, TeneoBio Inc., USA
A Novel CD3xPSMA Bispecific Antibody for Efficient T-Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release

Lynn A. Kamen, Genentech, Inc., USA
A Novel Cell-Based Assay for Predicting Bispecific Antibody Activity and its PK-PD Effects

Jason Lajoie, Compass Therapeutics, USA
A Versatile Platform for Efficient Affinity Optimization of Common Light Chain Bispecific Antibodies

Ahlam Qerqez, University of Texas at Austin, USA
Human Cytomegalovirus-Specific T Cell Receptor Engineered for High Affinity and Soluble Expression using Mammalian Cell Display

Diana Darowski, Roche Gylcart AG, Switzerland
Antibodies as Drugs: P329G LALA Mutated Antibodies Enable Precise Redirection of Anti-P329G-Based Chimeric Antigen Receptor T Cells (P329G-CAR-T cells)

Koen Wagner, AIMM Therapeutics, Netherlands
AT1413 T-Cell Engager Activity Is Determined by T-Cell Engager Format Valency

Phillip Liu, Sound Biologics, USA
Development of MabPair Technology, a Novel Platform for Producing Bifunctional Antibody Products

Brandy R. White, California State University, Fresno, USA
Humanization of a MUC16 Specific Monoclonal Antibody for the Treatment of Pancreatic Cancer

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Antibody Engineering
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
* James A. Ernst, Genentech, Inc., USA

Janine Schuurman, Genmab B.V., Netherlands
Engineering Non-Classical Antibody Formats Inspired by Nature

Feng Wang, Chinese Academy of Sciences, China
A Tumor Targeted Immune Checkpoint Blocker

Germaine Fuh, 23andMe, USA
Engineering Antibody Specificity and Stability Using Deep Sequencing

Aliza Borenstein-Katz, Weizmann Institute, Israel
Short Talk: Optimization of Antibody Anti Pancreatic Cancer Marker

Chia Yin Lee, Singapore Immunology Network, Singapore
Short Talk: Engineering the Fragment Crystallizable (Fc) Region of Antibody for Dendritic Cell-Based Vaccine

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 1

Breckenridge Ballroom

TUESDAY, APRIL 9

07:00—08:00
Breakfast

Summit Gallery
08:00—11:15
Bispecific and Engineered Antibodies for Cancer Immunotherapy
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
* Andreas G. Plückthun, University of Zürich, Switzerland

Nai-Kong V. Cheung, Memorial Sloan-Kettering Cancer Center, USA
Cancer Immunotherapy and Radioimmunotherapy with Bispecific Antibodies

Christian Klein, Roche, Switzerland
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy

Coffee Break

John R. Desjarlais, Xencor, Inc., USA
Bispecific Antibodies for T Cell Recruitment and T Cell Activation

Yvonne Y. Chen, University of California, Los Angeles, USA
Engineering Next-Generation Chimeric Antigen Receptors

Udaya S Rangaswamy, Teneobio, USA
Short Talk: A Novel T-Cell Bispecific Antibody Platform for Efficient T Cell-Mediated Killing of Tumor Cells with Minimal Cytokine Release

Lina Bartels, AIMM Therapeutics & Amsterdam University Medical Center, Netherlands
Short Talk: A T-Cell Engager Based on a Unique AML Patient-Derived Anti-CD43 Antibody Has a Strong Anti-AML Activity in vivo without Affecting Normal Hematopoietic Cells

Chad May, Maverick Therapeutics, USA
Short Talk: COBRA: A Novel Conditionally Active Bispecific Antibody that Regresses Established Solid Tumors in Mice

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Breckenridge Ballroom
13:00—22:00
Poster Viewing

Breckenridge Ballroom
16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Antibodies for Infectious Diseases
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
* Christoph Rader, The Scripps Research Institute, USA

David D. Ho, Aaron Diamond AIDS Research Center, USA
A Bispecific Antibody, 10E8.4/iMab, for HIV Therapy and Prevention

JoAnn A. Suzich, AstraZeneca, USA
Antibodies for the Prevention and Treatment of Viral Infections

Kartik Chandran, Albert Einstein College of Medicine, USA
Development of Engineered and Natural Antibodies as Anti-Ebola Therapeutics

Sisi Shan, Tsinghua University, China
Short Talk: Broad and Potent Bispecific Neutralizing Antibodies against Filovirus

Anna Zumsteg, Regeneron Pharmaceuticals, USA
Short Talk: Staphylococcus Aureus Specific Monoclonal Antibodies that Escape Binding to Protein A Protect against Invasive Disease

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
19:30—22:00
Poster Session 2

Breckenridge Ballroom

WEDNESDAY, APRIL 10

07:00—08:00
Breakfast

Summit Gallery
08:00—11:15
Antibody Drug Conjugates
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
* Jennifer R. Cochran, Stanford University, USA

Ronit Mazor, MedImmune, USA
Immunogenicity of Recombinant Immunotoxins and Approaches to Mitigate It

Richard J. Gregory, ImmunoGen, Inc., USA
Optimizing the Activity of Antibody Drug Conjugates

Coffee Break

John M. Lambert, , USA
Site-Specific Conjugation in ADC Design: Panacea or Hype? Lessons from a Case Study with a Maytansinoid Conjugate

W. Michael Kavanaugh, Cytomx Therapeutics, USA
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies

Armine Matevossian, Novartis Institutes for BioMedical Research, USA
Short Talk: Comprehensive Profiling of the Immune-Modulatory Properties of a Cytotoxic ADC Reveals Unique Contributions by the Antibody Component of the Drug

Bradley Pearse, Magenta Therapeutics, USA
Short Talk: Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients

Brian H. Santich, Gerstner Sloan-Kettering Graduate School, USA
Short Talk: Self-Assembling and Disssembling (SADA) Bispecific Antibodies (BsAb) for 2-Step Pretargeted RadioImmunotherapy (PRIT)

11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—19:00
Delivering Antibodies into the Brain
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
* Germaine Fuh, 23andMe, USA

Joy Yu Zuchero, Denali Therapeutics Inc, USA
CNS Delivery of Therapeutic Proteins using a Novel Fc Fragment Blood-Brain Barrier Transport Vehicle Approach

Per-Ola Freskgård, F. Hoffmann-La Roche, Switzerland
Crossing the Blood-Brain Barrier with Antibodies to Access Brain Targets

Allan Jensen, Lundbeck, Denmark
Antibody-Based Therapies for Neurodegenerative Diseases

Mathieu Oosterlaken, Institut de Génomique Fonctionelle, France
Short Talk: Engineering Pharmacology Active Nanobodies to Target mGlu2 Receptor in the Brain

Chiara Figazzolo, University of Cambridge, UK
Short Talk: Rational Design and Systematic Optimization of Antibodies against the Aggregation of the Aβ42 Peptide

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom

THURSDAY, APRIL 11

07:00—08:00
Breakfast

Summit Gallery
08:00—11:00
Bispecific Antibodies and Antibody Like Molecules
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
* Christian Klein, Roche, Switzerland

Christoph Rader, The Scripps Research Institute, USA
Chemically Programmed Bispecific Antibodies

James A. Ernst, Genentech, Inc., USA
A Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH

Coffee Break

Andreas G. Plückthun, University of Zürich, Switzerland
Engineering DARPins for Delivery into Cells

Krzysztof Masternak, NovImmune SA, Switzerland
Bispecific CD47 Antibodies for Treatment of Cancer

Peter J. Hudson, Avipep Pty Ltd, Australia
Short Talk: Engineered Antibody Fragments Precisely Loaded with Diagnostic and Therapeutic Payloads with First-in-Man Biodistribution in Cancer Metastases

Leandrew A. Dailey, Albert Einstein College of Medicine, USA
Short Talk: Engineering Next-Generation Bispecific Antibodies against Filoviruses

11:00—17:00
On Own for Lunch

14:30—16:30
Workshop 2: Antibodies for Immunological Applications

Colorado Ballroom
Mark S. Cragg, University of Southampton, UK

Nicole Piché-Nicholas, Pfizer, USA
Changes in Complementarity-Determining Regions Significantly Alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics

Trevor RF Smith, Inovio Pharmaceuticals, USA
Active Immunoprophylaxis Employing DNA-Encoded Monoclonal Antibodies (dMAbs™)

Olivia Vergnolle, Albert Einstein College of Medicine, USA
Dengue Virus Glycoprotein E DIII Epitope Engineering for Broadly Neutralizing Antibodies Enhancement

Masahiro Yasunaga, National Cancer Center, Japan
Development of Next-Generation Antibody Therapeutics against Cancer and Autoimmune Disease Utilizing DDS and Molecular Imaging

Henry Wilson, The Scripps Research Institute, USA
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries

Gregory Mann, École Polytechnique Fédérale de Lausanne, Switzerland
Using Monobodies to Target Cytoplasmic Oncoproteins

16:30—17:00
Coffee Available

Colorado Ballroom Foyer
17:00—18:45
Beyond Checkpoint Blockade: Novel Approaches for Immunotherapy
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
Mikael C. I. Karlsson, Karolinska Institutet, Sweden
Anti-Marco Antibodies in Tumor Immunotherapy

Sean Hua Lim, University of Southampton, UK
Optimizing Anti-Tumor Immunity through Manipulation of the Innate-Adaptive Interface using CD27 Agonists

Sapna Yadavilli, GlaxoSmithKline, USA
GSK 3359609 a Non-T Cell Depleting IgG4 Anti-ICOS Antibody

Wen Jie Chin, Agency for Science, Technology and Research, Singapore
Short Talk: Engineering Antibodies to Engage TRIM21 Improves Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Registered attendees can view abstracts starting on 03/07/2019

Colorado Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Breckenridge Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Breckenridge Ballroom

FRIDAY, APRIL 12

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

AbbVie Inc. Bioverativ Therapeutics
ImmunoGen, Inc. Incyte Corporation
Merck & Co., Inc. MorphoSys AG
Roche Valerion Therapeutics

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI145248-01

Funding for this conference was made possible (in part) by 1R13AI145248-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

American Association for Cancer Research (AACR) American Society of Gene & Cell Therapy (ASGCT)

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



CytomX Therapeutics, Inc.


Denali Therapeutics Inc.


Genmab B.V.


ImmunoGen, Inc.


Lundbeck


NovImmune SA


Regeneron Pharmaceuticals, Inc.


Roche


Xencor, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676